not generalizable to other RCTs. Goal Attainment Scaling (GAS); Global Measures. Clinician Interview-Based Impression of Change plus caregiver input ( CIBIC. interview [CIBIC-plus]). The ADAS- cog, disease assessment in dementia scale, and neuropsychiatric inventory are recorded by supervising site investigator, but . The Clinician Interview-Based Impression of Change, plus carer interview (CIBIC -Plus), is widely used in antidementia drug trials. It comprises Likert scales for.

Author: Zolole Dijora
Country: Bolivia
Language: English (Spanish)
Genre: Software
Published (Last): 2 September 2012
Pages: 276
PDF File Size: 13.87 Mb
ePub File Size: 19.99 Mb
ISBN: 223-9-54802-908-2
Downloads: 31962
Price: Free* [*Free Regsitration Required]
Uploader: Tut

CIBIC Plus-J Assessment Using a Videotaped Method in Alzheimer’s Disease Patients

Epub Dec Epub Jul 7. Materials and Methods Informed Cbiic Informed written consent was obtained from patients and caregivers before their enrollment into this clinical trial.

Development of a functional measure for persons with Alzheimer’s disease: Dement Geriatr Cogn Dis Extra. Latha Velayudhan Simon Lovestone.

Search Our Scientific Publications & Authors

In addition, an ethics committee approved the conduct upon request at some sites and their institutional review boards. This may make galantamine an attractive option for patients starting treatment for Alzheimer’s disease ADbut also for those who have not benefited from their current therapy. To evaluate the effects of galantamine withdrawal, and compare this with uninterrupted therapy, two 6-week double-blind withdrawal studies Studies 1 and 2 were performed.

Acupuncture for patients with mild to moderate Alzheimer’s disease: Alzheimer’s disease AD has become a major public health problem around the world due to its increasing prevalence, long duration, caregiver burden, and high financial cost of care.

Expert Opin Pharmacother Apr 6;19 5: We would like to thank the following principal investigators and their staffs for patient recruiting, interviews and video-recording: To evaluate the efficacy and safety of memantine in patients with mild to moderate Alzheimer’s disease AD receiving cholinesterase inhibitor ChEI treatment. We examined how this change compared with measures of clinical meaningfulness.


Using data from a large prospective clinical trial comparing two doses of donepezil in patients with moderate to severe AD, we performed a post hoc analysis to determine whether a higher dose of donepezil was associated with greater benefits in language function.

Ann Neurol Jul;72 1: J Neurol Neurosurg Psychiatry Oct 12;78 The role of memantine as a treatment for Alzheimer’s disease AD has been controversial. Please review our privacy policy.

CIBIC Plus-J Assessment Using a Videotaped Method in Alzheimer’s Disease Patients

Acetylcholinesterase inhibitor AChEI and memantine are recognized drug treatments with limited clinical efficacy. Int Psychogeriatr Jun;19 3: We tested the efficacy and tolerability of one-year treatment with memantine 10 mg bid in behavioral variant frontotemporal dementia bvFTD.

The global severity scales that have been ecale include: To highlight the utility of using an effect size analysis to communicate the effectiveness of treatment interventions. Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http: Informed written consent was obtained from patients and caregivers before their enrollment into this clinical trial.

This is a secondary analysis of a 12 month open-label study of patients 71 women diagnosed with mild to moderate AD treated with mg of donepezil daily. Latrepirdine may modulate several targets involved in AD pathology, including lipid sfale, mitochondrial permeability, voltage-gated calcium ion scqle as well as neurotransmitter receptor activity, and thus potentially represents both a symptomatic and disease-modifying intervention.


Memantine treatment in patients with mild to moderate Alzheimer’s disease: Patients were randomized to donepezil 10 mg daily or placebo for 24 weeks. Dement Geriatr Cogn Disord 5;40 The option of clinical research coordinators using home video cameras should be considered. This study explored outcomes in subjects with AD transitioning from donepezil because of insufficient tolerability or efficacy.

Epub Oct Neurol Sci Sep 22;36 9: Utility of an effect size analysis for communicating treatment effectiveness: Memantine has been approved by the Food and Drug Administration for the treatment of moderate-to-severe Alzheimer’s disease AD. Kagawa University, Miki, Japan. However, CIBIC plus-J scalf generally conducted at clinical sites, and we consider that greater variability would arise among raters at such sites in accordance with their experience.

Author information Copyright and License information Disclaimer. This was a single-center, 6-month, open, uncontrolled study. Interviewers agreed to their voice being recorded before each interview.

Prog Neuropsychopharmacol Biol Psychiatry Aug 25;32 6: The dcale cortex and the olfactory bulb, critical areas for olfactory function, are rich in acetylcholine, the neurotransmitter implicated in AD pathology and treatment. Memantine in Japanese patients with moderate to severe Alzheimer’s disease: Donepezil preserves cognition and global function in patients with severe Alzheimer disease.